Anticoagulant versus antiplatelet treatment for secondary stroke prevention in patients with active cancer.

ABSTRACT:

Background

Approximately 5-10% of patients with acute ischemic stroke (AIS) have known active cancer. These patients are at high risk for both recurrent AIS and major bleeding. The optimal antithrombotic strategy for cancer-related stroke is uncertain. This study compared clinical outcomes among patients with cancer-related stroke treated with anticoagulant versus antiplatelet therapy for secondary prevention.

Methods

We identified consecutive patients with AIS and active cancer hospitalized at our comprehensive stroke center from 2015 through 2020. Patients with cardioembolic mechanisms were excluded. We used Cox regression and inverse probability of treatment weighting (IPTW) analyses to evaluate the associations between type of antithrombotic therapy at discharge (anticoa

SUBMITTER: Kielkopf MC 

PROVIDER: S-EPMC12479245 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature